Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Othman Laraki
AddedMar 31, 2024
UpdatedJul 3, 2026
Othman Laraki

Othman Laraki

Board Member, American Cancer Society

CrunchbaseLinkedIn

Othman Laraki's Career

American Cancer Society
American Cancer Society

Atlanta, GA, US

Board Member· Board
Frontier Medicines
Frontier Medicines

South San Francisco, CA, US

Board Member· Board
Color
Color

Burlingame, CA, US

Co-Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Othman Laraki's Career

American Cancer Society
American Cancer Society
NonprofitNonprofit$2M8.3k1913Atlanta, GA, US
Board Member· Board

Recent news

Serena-backed health tech lands first FDA approval for home cervical cancer testTechCrunch · 2025

Leadership at American Cancer Society

Terri McClementsTerri McClementsBoard Member
Jigar RaythathaJigar RaythathaBoard Member
Brian MarlowBrian MarlowBoard Member
Kathy GallagherKathy GallagherBoard Member
Jeffrey GoffmanJeffrey GoffmanBoard Member
Jeffrey KeanJeffrey KeanBoard Member
Frontier Medicines
Frontier Medicines
Series B$244M1282018South San Francisco, CA, US
Board Member· Board

Leadership at Frontier Medicines

Chris VarmaChris VarmaBoard Member
Daniel NomuraDaniel NomuraCo-Founder
Roberto ZoncuRoberto ZoncuCo-Founder

Similar to Frontier Medicines

Ampersand BiomedicinesAmpersand BiomedicinesBoston, MA, USTherapeuticsest. 2020Ampersand BiomedicinesBoston, MA, US · est. 2020

Ampersand Biomedicines: Innovating disease-targeted programming therapeutics via our AND™ Platform.

Series D · $50M30
ProFound TherapeuticsProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35
Faze MedicinesFaze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40
Totus MedicinesTotus MedicinesEmeryville, CA, USDrug Developmentest. 2020Totus MedicinesEmeryville, CA, US · est. 2020

Totus Medicines: Revolutionizing chemical biology to create life-changing treatments for untreatable diseases.

Series B · $106M40
Color
Color
Series E$482M4742015Burlingame, CA, US
Co-Founder & CEO· C-Suite · Management

Leadership at Color

Elad GilElad GilCo-Founder
Hemant TanejaHemant TanejaBoard Member

Similar to Color

InvitaeInvitaeSan Francisco, CA, USGenetic Testingest. 2010InvitaeSan Francisco, CA, US · est. 2010

Invitae Corp., a global genetic information company, specializes in diagnostics, oncology, pediatrics, and hereditary screening.

Public · $2.5B1.7k
23andMe23andMeSunnyvale, CA, USGenetic Testingest. 200623andMeSunnyvale, CA, US · est. 2006

23andMe: A biotech firm offering direct-to-consumer genetic testing for ancestry and health predispositions.

Public · $1.1B816
GeneticaGeneticaSan Francisco, CA, USGene Testingest. 2017GeneticaSan Francisco, CA, US · est. 2017

San Francisco-based Genetica pioneers in gene testing technology for precision medicine in Asia.

Seed · $2.5M75
Pathway GenomicsPathway GenomicsSan Diego, CA, USGenetic Testsest. 2008Pathway GenomicsSan Diego, CA, US · est. 2008

San Diego-based Pathway Genomics offers globally accredited genetic tests for various health risks.

Series E · $43M175

Othman Laraki's Co-Investors

Anthony \"Pomp\" PomplianoAnthony \"Pomp\" PomplianoCo-invested · Exponential DeFi SeedZach PerretZach PerretCo-invested · Exponential DeFi SeedYoucef Es-skouriYoucef Es-skouriCo-invested · Exponential DeFi SeedHenrique DubugrasHenrique DubugrasCo-invested · Exponential DeFi SeedBalaji SrinivasanBalaji SrinivasanCo-invested · Exponential DeFi SeedAdam NashAdam NashCo-invested · Exponential DeFi SeedGokul RajaramGokul RajaramCo-invested · Exponential DeFi SeedEric RiesEric RiesCo-invested · Seed

Othman Laraki's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Othman Laraki

Bill VeghteBill VeghteBoard Member · MultiplanSharat SatyanarayanaSharat SatyanarayanaCEO · Color ITMike HerringMike HerringBoard Member · Next Frontier CapitalEvan KirkhamEvan KirkhamCo-Founder · ColorcastTina MalhotraTina MalhotraCEO · Color FactoryJames GiancottiJames GiancottiCo-Founder · Bigcolors